Generalized treatment effects for clinical trials.

Practice in the analysis of clinical trials with continuously measured endpoints is to focus on the difference or percentage change in mean or median response. However, treatments may have effects on the distribution of responses other than on the average response. We sought an approach to such generalized treatment effects that: (i) targets a parameter that is easily understood by our clinical colleagues; and (ii) employs confidence intervals as the basis for inference. We consider one such approach based on work in reliability theory, namely setting Pr[Y>X] as the target parameter, and compare this approach to an earlier one due to O'Brien. The two approaches have similar properties when they both seek to reject the null hypothesis of no effect due to different variances but differ when the larger variance corresponds to the larger mean. In that case, our approach views that the larger variance attenuates the effect of the larger mean. Out suggested approach applies easily to positive control (clinical) equivalence trials.

[1]  On the use of the generalized t and generalized rank-sum statistics in medical research. , 1992, Statistics in medicine.

[2]  Y. Hochberg,et al.  Alternative Estimation Procedures for Pr(X < Y) in Categorized Data , 1986 .

[3]  A. Munk Equivalence and Interval Testing for Lehmann's Alternative , 1996 .

[4]  Irwin Guttman,et al.  A comparison of three point estimators for P(Y < X) in the normal case , 1987 .

[5]  S. Wellek Basing the Analysis of Comparative Bioavailability Trials on an Individualized Statistical Definition of Equivalence , 1993 .

[6]  Z. Birnbaum,et al.  A Distribution-Free Upper Confidence Bound for $\Pr \{Y < X\}$, Based on Independent Samples of $X$ and $Y$ , 1958 .

[7]  Walter W. Hauck,et al.  Some Issues in the Design and Analysis of Equivalence Trials , 1999 .

[8]  R. Blair,et al.  Comparison of two tests useful in situations where treatment is expected to increase variability relative to controls. , 1993, Statistics in medicine.

[9]  W. Hauck,et al.  Types of bioequivalence and related statistical considerations. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[10]  Douglas A. Wolfe,et al.  On Constructing Statistics and Reporting Data , 1971 .

[11]  R. Blair New critical values for the generalized t and generalized rank-sum procedures , 1991 .

[12]  R Schall,et al.  On population and individual bioequivalence. , 1993, Statistics in medicine.

[13]  H. Ury,et al.  On Distribution-Free Confidence Bounds for Pr{Y < X} , 1972 .

[14]  A parametric approach to population bioequivalence. , 1997, Statistics in medicine.

[15]  Stephen Senn,et al.  LETTER TO THE EDITOR: Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses, by D. M. Rom and E. Hwang, Statistics in Medicine, 15, 1489–1505 (1996) , 1997 .

[16]  Irwin Guttman,et al.  Statistical inference for Pr(Y < X): The normal case , 1986 .

[17]  Robert W. Mee Confidence Intervals for Probabilities and Tolerance Regions Based on a Generalization of the Mann-Whitney Statistic , 1990 .

[18]  P. O'Brien,et al.  Comparing Two Samples: Extensions of the t, Rank-Sum, and Log-Rank Tests , 1988 .

[19]  F. Downton The Estimation of Pr (Y < X) in the Normal Case , 1973 .

[20]  G. Glass Primary, Secondary, and Meta-Analysis of Research1 , 1976 .

[21]  P. K. Tandon,et al.  Application of new two-sample tests to data from a randomized placebo-controlled heart-failure trial. , 1990, Statistics in medicine.

[22]  D. L. Hanson,et al.  Nonparametric Upper Confidence Bounds for Pr{Y < X} and Confidence Limits for Pr{Y < X} When X and Y are Normal , 1964 .

[23]  Distribution-free Confidence Intervals for Pr(X1 < X2) , 1987 .